NTLA - Why Intellia Therapeutics Stock Is Surging Tuesday | Benzinga
Intellia Therapeutics Inc (NYSE: NTLA) shares are trading higher Tuesday after the company announced it received European Union orphan drug designation for NTLA-2002.
What To Know: The European Commission granted orphan drug designation to the company's in vivo CRISPR-based investigational therapy NTLA-2002 for the treatment of hereditary angioedema.
The designation provides incentives to develop therapies for rare diseases where there are either no satisfactory treatment options or significant benefit to those affected ...